Intraocular inflammation after intravitreal ranibizumab injections.
Fauser
Sascha
S
Schroeder
Sabine
S
Caramoy
Albert
A
Kirchhof
Bernd
B
Lappas
Alexandra
A
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000867:Anterior Chamber / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002442:Ceftazidime / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy; D000069579:Ranibizumab; D019233:Retreatment; D014640:Vancomycin / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body / Q000473:pathology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D014640:Vancomycin; D002442:Ceftazidime; D000069579:Ranibizumab